Initial tests have been promising, but what happens if none of the trials pans out?
The race for a COVID-19 vaccine is unprecedented: 198 potential vaccines are now in development, and that development is happening faster than it ever has in history. Moderna, for example, finalized its vaccine just days after Chinese researchers released the genetic sequence of the new coronavirus in January. Two months later, the first volunteer was dosed with the vaccine. Last week, the company published positive Phase I trial results showing that the vaccine seems safe and generates an immune response; days later, Oxford University researchers published similarly promising results.
Read the full article here.
This content was originally published by Fast Company. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Fast Company